Dimensional Fund Advisors Portfolio holdings
Dimensional Fund Advisors (DFA), founded in 1981 by David Booth and Rex Sinquefield and headquartered in Austin, Texas, is an investment management firm renowned for its evidence-based, low-cost approach to investing, grounded in academic research from Nobel laureates like Eugene Fama and Kenneth French. Managing hundreds of billions in assets, DFA focuses on systematic, passive strategies that tilt toward factors like small-cap, value, and profitability stocks, primarily through mutual funds and institutional portfolios rather than retail brokerage services. The firm’s philosophy eschews market timing and stock picking, instead emphasizing diversification and efficient market exposure, often requiring investors to access its funds through approved financial advisors. With a global presence and a reputation for disciplined, data-driven investing, DFA has carved a unique niche in the industry, blending academic rigor with practical application.
Top Buys
| 1 |
Apple
AAPL
|
+$564M |
| 2 |
UnitedHealth
UNH
|
+$439M |
| 3 |
Johnson & Johnson
JNJ
|
+$353M |
| 4 |
Amazon
AMZN
|
+$200M |
| 5 |
Microsoft
MSFT
|
+$198M |
Top Sells
| 1 |
EXE
Expand Energy Corporation Common Stock
EXE
|
+$344M |
| 2 |
JPMorgan Chase
JPM
|
+$293M |
| 3 |
Kellanova
K
|
+$165M |
| 4 |
SUM
Summit Materials, Inc. Class A Common Stock
SUM
|
+$159M |
| 5 |
AZPN
Aspen Technology Inc
AZPN
|
+$156M |
Sector Composition
| 1 | Technology | 18.85% |
| 2 | Financials | 18.69% |
| 3 | Industrials | 11.91% |
| 4 | Healthcare | 10.42% |
| 5 | Consumer Discretionary | 10.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2901
Identive
INVE
$90.1M
| $900K | ﹤0.01% |
282,303
| – | – |
|
2902
Crown Crafts
CRWS
$32.2M
| $894K | ﹤0.01% |
245,714
-1,823
| -0.7% | -$6.64K |
|
2903
Semtech
SMTC
$5.26B
| $894K | ﹤0.01% |
25,984
+8,413
| +48% | +$289K |
|
2904
American Healthcare REIT
AHR
$7.21B
| $889K | ﹤0.01% |
+29,354
| New | +$889K |
|
2905
Black Diamond Therapeutics
BDTX
$185M
| $888K | ﹤0.01% |
572,470
-88,966
| -13% | -$138K |
|
|
LINE
2906
Lineage, Inc. Common Stock
LINE
$9.54B
| $882K | ﹤0.01% |
+15,036
| New | +$882K |
|
2907
Axsome Therapeutics
AXSM
$6.27B
| $872K | ﹤0.01% |
+7,478
| New | +$872K |
|
2908
Optical Cable Corp
OCC
$52.2M
| $868K | ﹤0.01% |
311,190
+2,252
| +0.7% | +$6.28K |
|
2909
Sanara MedTech
SMTI
$318M
| $865K | ﹤0.01% |
28,009
+12,084
| +76% | +$373K |
|
2910
Outdoor Holding Company Common Stock
POWW
$169M
| $864K | ﹤0.01% |
626,111
-128,199
| -17% | -$177K |
|
2911
Auburn National Bancorp
AUBN
$97M
| $861K | ﹤0.01% |
39,882
+258
| +0.7% | +$5.57K |
|
2912
Tango Therapeutics
TNGX
$758M
| $830K | ﹤0.01% |
605,290
-57,486
| -9% | -$78.8K |
|
2913
C4 Therapeutics
CCCC
$193M
| $823K | ﹤0.01% |
514,155
-9,776
| -2% | -$15.7K |
|
2914
MacroGenics
MGNX
$111M
| $820K | ﹤0.01% |
645,625
-71,663
| -10% | -$91K |
|
2915
HighPeak Energy
HPK
$926M
| $816K | ﹤0.01% |
64,449
+6,198
| +11% | +$78.5K |
|
2916
Harvard Bioscience
HBIO
$19.5M
| $814K | ﹤0.01% |
1,437,808
-227,305
| -14% | -$129K |
|
2917
SWK Holdings
SWKH
$177M
| $808K | ﹤0.01% |
58,644
| – | – |
|
2918
Workiva
WK
$4.56B
| $805K | ﹤0.01% |
+10,609
| New | +$805K |
|
2919
Ubiquiti
UI
$35.3B
| $801K | ﹤0.01% |
2,582
+167
| +7% | +$51.8K |
|
2920
Savara
SVRA
$665M
| $800K | ﹤0.01% |
288,674
+145,013
| +101% | +$402K |
|
2921
Trevi Therapeutics
TRVI
$926M
| $799K | ﹤0.01% |
126,924
-7,429
| -6% | -$46.8K |
|
2922
CF Bankshares
CFBK
$164M
| $791K | ﹤0.01% |
35,890
+7,180
| +25% | +$158K |
|
2923
Canterbury Park Holding Corp
CPHC
$84.2M
| $789K | ﹤0.01% |
43,225
| – | – |
|
2924
CG Oncology
CGON
$2.57B
| $788K | ﹤0.01% |
+32,158
| New | +$788K |
|
2925
Hagerty
HGTY
$1.2B
| $783K | ﹤0.01% |
86,584
+24,550
| +40% | +$222K |
|